PD-L1 Blockade for Cancer Treatment: MEDI4736

Ibrahim, Ramy; Stewart, Ross; Shalabi, Aiman

doi:10.1053/j.seminoncol.2015.02.007

Cited by 83 publications

(56 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are currently numerous early phase trials investigating the anti-PD-L1 antibody MEDI4736, following promising preclinical evidence [13][14][15]. MEDI4736 is being investigated in patients with advanced solid tumours (NCT01693562, NCT01938612, Table 1) and in selected GI tumour types, discussed below [16].…”

Section: Medi4736mentioning

confidence: 99%

PD-1 and PD-L1 blockade in gastrointestinal malignancies

Lote

Cafferkey

Chau

2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

Section: Medi4736mentioning

confidence: 99%

PD-1 and PD-L1 blockade in gastrointestinal malignancies

Lote

Cafferkey

Chau

2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…Folglich würde die T-Zell-Aktivierung auch weniger unspezifisch ausfallen als bei der CTLA-4-Blockade in der Frühphase der Immunantwort, womit möglicherweise auch die niedrigere Rate an immunvermittelten Nebenwirkungen zusammenhängt, die unter einer Antikörper-Blockade von PD-1/PD-L1-Signalen beobachtet wurden [30,31,32,33]. …”

Section: Optimierung Durch Kombination?unclassified

Rationale, Visionen und Grenzen der Immunonkologie: Checkpoint-Inhibition als neue Therapiesäule der Tumortherapie

Hauschild

Mohr

2015

Oncol Res Treat

View full text Add to dashboard Cite

“…Response rates of 25-43% for the FDAapproved anti-PD-1 monoclonal antibodies have been seen in metastatic melanoma (Table 1). [43][44][45][46][47] PD-1, PD-L1 and PD-L2 RNA and protein have been detected in BC tumors. 48 PD-1 expression is associated with poor prognosis in breast and epithelial-derived cancers.…”

Section: Negative Immune Regulators and Breast Cancermentioning

confidence: 99%

A review of the importance of immune responses in luminal B breast cancer

et al. 2017

View full text Add to dashboard Cite

Historically, the immune environment was not considered an important target for breast cancer treatment. However, the association of lymphocytic infiltrates in triple negative and HER-2 over-amplified breast cancer subtypes with better outcomes, has provoked interest in evaluating the role of the immune system in the luminal B subtype that accounts for 39% of breast cancers and has a poor patient prognosis. It is unknown which immunosuppressive cell types or molecules (e.g., checkpoint molecules) are relevant, or where measurement is most informative. We hypothesize that a profound immunosuppressive tumor and/or lymph node milieu is prognostic and impacts on responses to therapies.

show abstract

PD-L1 Blockade for Cancer Treatment: MEDI4736

Cited by 83 publications

References 23 publications

PD-1 and PD-L1 blockade in gastrointestinal malignancies

PD-1 and PD-L1 blockade in gastrointestinal malignancies

Rationale, Visionen und Grenzen der Immunonkologie: Checkpoint-Inhibition als neue Therapiesäule der Tumortherapie

A review of the importance of immune responses in luminal B breast cancer

Contact Info

Product

Resources

About